X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3632) 3632
Book Chapter (13) 13
Dissertation (5) 5
Magazine Article (4) 4
Publication (4) 4
Book / eBook (3) 3
Conference Proceeding (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2477) 2477
animals (1300) 1300
male (1032) 1032
proprotein convertase 9 (954) 954
female (902) 902
proprotein convertases (864) 864
cholesterol (838) 838
mice (725) 725
biochemistry & molecular biology (697) 697
pcsk9 (654) 654
cholesterol, ldl - blood (633) 633
middle aged (590) 590
hypercholesterolemia (587) 587
serine endopeptidases - genetics (549) 549
cardiac & cardiovascular systems (521) 521
proprotein convertase 9 - antagonists & inhibitors (492) 492
lipids (459) 459
low density lipoproteins (456) 456
serine endopeptidases - metabolism (453) 453
familial hypercholesterolemia (442) 442
proprotein convertases - metabolism (439) 439
mutation (437) 437
atherosclerosis (410) 410
adult (401) 401
statins (395) 395
proprotein convertases - genetics (387) 387
risk factors (380) 380
aged (373) 373
furin (368) 368
anticholesteremic agents - therapeutic use (366) 366
endocrinology & metabolism (362) 362
cell biology (361) 361
expression (361) 361
peripheral vascular disease (341) 341
amino acid sequence (335) 335
proteins (325) 325
hypercholesterolemia - drug therapy (320) 320
proprotein convertase subtilisin/kexin type 9 (314) 314
molecular sequence data (310) 310
research (309) 309
cardiovascular disease (305) 305
pharmacology & pharmacy (304) 304
proprotein convertases - antagonists & inhibitors (303) 303
antibodies, monoclonal - therapeutic use (302) 302
subtilisin/kexin type 9 (301) 301
receptors, ldl - metabolism (298) 298
lipoproteins (293) 293
proprotein convertase 9 - metabolism (289) 289
analysis (282) 282
genetic aspects (280) 280
receptors, ldl - genetics (279) 279
monoclonal-antibody (277) 277
proprotein convertase (272) 272
ldl cholesterol (265) 265
risk (264) 264
treatment outcome (264) 264
density-lipoprotein cholesterol (263) 263
abridged index medicus (254) 254
mutations (253) 253
proprotein convertase 9 - genetics (253) 253
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (252) 252
cardiovascular (232) 232
subtilisin (227) 227
physiological aspects (226) 226
cardiovascular diseases (224) 224
biomarkers - blood (222) 222
safety (219) 219
efficacy (217) 217
heterozygous familial hypercholesterolemia (216) 216
gene expression (215) 215
hyperlipoproteinemia type ii - genetics (213) 213
rats (213) 213
cell line (212) 212
gene (212) 212
kexin (212) 212
ldl receptor (211) 211
proprotein convertase subtilisin (207) 207
enzymes (204) 204
coronary-heart-disease (200) 200
low density lipoprotein (200) 200
autosomal-dominant hypercholesterolemia (198) 198
ldl (194) 194
metabolism (191) 191
activation (190) 190
protein processing, post-translational (184) 184
cardiovascular diseases - prevention & control (182) 182
health aspects (182) 182
kexin type 9 (178) 178
research article (178) 178
identification (177) 177
multidisciplinary sciences (177) 177
subtilisins - metabolism (177) 177
liver (175) 175
mice, knockout (175) 175
monoclonal antibodies (175) 175
phenotype (175) 175
evolocumab (172) 172
disease (170) 170
receptor (168) 168
double-blind (166) 166
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3562) 3562
German (45) 45
Japanese (40) 40
Spanish (26) 26
Chinese (12) 12
French (12) 12
Czech (9) 9
Italian (9) 9
Portuguese (7) 7
Russian (7) 7
Norwegian (6) 6
Hungarian (4) 4
Turkish (3) 3
Danish (2) 2
Polish (2) 2
Swedish (2) 2
Croatian (1) 1
Dutch (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation (New York, N.Y.), ISSN 0009-7322, 10/2015, Volume 132, Issue 17, pp. 1648 - 1666
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the regulation of cholesterol homeostasis... 
Antibodies, monoclonal | Clinical trial | PCSK9 protein, human | antibodies, monoclonal | clinical trial | CARDIAC & CARDIOVASCULAR SYSTEMS | LOWERING THERAPY | MONOCLONAL-ANTIBODY | DENSITY-LIPOPROTEIN-CHOLESTEROL | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | STATIN-INTOLERANT PATIENTS | HEALTHY-VOLUNTEERS | CORONARY-HEART-DISEASE | PLASMA LDL CHOLESTEROL | PCSK9 GENE | Proprotein Convertases - antagonists & inhibitors | Cardiovascular Diseases - prevention & control | Humans | Serine Endopeptidases - physiology | Antibodies, Monoclonal - therapeutic use | Intestines - metabolism | Structure-Activity Relationship | Cardiovascular Diseases - enzymology | Molecular Targeted Therapy | Cardiovascular Diseases - genetics | Proprotein Convertases - genetics | Incidence | Brain - metabolism | RNA Interference | Oligonucleotides, Antisense - therapeutic use | Serine Endopeptidases - genetics | Cardiovascular Diseases - epidemiology | Protein Structure, Tertiary | Genetic Predisposition to Disease | Antibodies, Monoclonal, Humanized - therapeutic use | Serine Endopeptidases - deficiency | Liver - metabolism | Receptors, LDL - metabolism | Serine Endopeptidases - chemistry | Clinical Trials as Topic | Proprotein Convertases - chemistry | Proprotein Convertases - deficiency | Proprotein Convertases - physiology | Animals | RNA, Small Interfering - therapeutic use | Adipocytes - metabolism | Cholesterol, LDL - metabolism | Hyperlipoproteinemias - genetics | Mice | Peptide Fragments - therapeutic use | Mutation | Proprotein Convertase 9 | Monoclonal antibodies | Clinical trials | Usage | Care and treatment | Dosage and administration | Cardiovascular diseases
Journal Article
PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 2, p. e0191895
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 383, Issue 9911, pp. 60 - 68
Summary Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | DOUBLE-STRANDED-RNA | PLASMA-CHOLESTEROL | METAANALYSIS | CARDIOVASCULAR-DISEASE | MONOCLONAL-ANTIBODY | HYPERCHOLESTEROLEMIA | STATINS | AMG 145 | ATORVASTATIN | Single-Blind Method | Serine Endopeptidases - biosynthesis | Humans | Middle Aged | RNA, Small Interfering - pharmacology | RNA, Small Interfering - adverse effects | Cholesterol, LDL - drug effects | Male | Healthy Volunteers | Proprotein Convertases - genetics | Dose-Response Relationship, Drug | Proprotein Convertases - biosynthesis | RNA Interference | Serine Endopeptidases - blood | Serine Endopeptidases - genetics | Adult | Cholesterol, LDL - blood | Female | Proprotein Convertases - blood | RNA, Small Interfering - administration & dosage | Genetic Therapy - adverse effects | Genetic Therapy - methods | Proprotein Convertase 9 | Enzymes | Research | Gene mutations | Properties | Gene expression | Identification and classification | Medical research | RNA | Low density lipoproteins | Anticholesteremic agents | Clinical trials | Aluminum compounds | Coronary heart disease | Cholesterol | Hypercholesterolemia | Analysis | Medicine, Experimental | Product development | Trans fatty acids | Blood proteins | Studies | Heart | Nanoparticles | Plasma | Nutrition research | Cardiovascular disease | Lipids | Mutation | Drug dosages | Statins
Journal Article
Annals of internal medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 40 - 51
Journal Article
Journal Article
Atherosclerosis, ISSN 0021-9150, 2014, Volume 236, Issue 1, pp. 54 - 61
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9858, pp. 2007 - 2017
Journal Article
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2003, Volume 100, Issue 3, pp. 928 - 933
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2013, Volume 62, Issue 16, pp. 1401 - 1408
.... Gain-of-function mutations of the proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with hypercholesterolemia and increased risk of cardiovascular events... 
Cardiovascular | Internal Medicine | atherosclerosis | proprotein convertase subtilisin/kexin type 9 | PCSK9 | LDL cholesterol | LDL receptor | atherosclerosis LDL cholesterol LDL receptor PCSK9 proprotein convertase subtilisin/kexin type 9 | NONHUMAN-PRIMATES | LDL-CHOLESTEROL | CARDIAC & CARDIOVASCULAR SYSTEMS | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | DENSITY-LIPOPROTEIN-CHOLESTEROL | SECRETED PCSK9 | RECEPTOR-MEDIATED ENDOCYTOSIS | STATIN THERAPY | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | SERINE-PROTEASE | Proprotein Convertases - antagonists & inhibitors | Dyslipidemias - complications | Humans | Lipoproteins, LDL - genetics | Proprotein Convertases - genetics | Molecular Targeted Therapy - trends | Serine Endopeptidases - genetics | Lipid Metabolism - genetics | Lipoproteins, LDL - metabolism | Molecular Targeted Therapy - methods | Receptors, LDL - genetics | Dyslipidemias - drug therapy | Atherosclerosis - drug therapy | Proprotein Convertases - metabolism | Risk Factors | Receptors, LDL - metabolism | Atherosclerosis - complications | Hypolipidemic Agents - pharmacology | Forecasting | Atherosclerosis - metabolism | Lipid Metabolism - drug effects | Dyslipidemias - metabolism | Serine Endopeptidases - metabolism | Mutation | Proprotein Convertase 9 | Hypertension | Hypercholesterolemia | Low density lipoproteins | Mortality | Atherosclerosis | Drug therapy | Statins | Cholesterol | Protein binding | Studies | Rodents
Journal Article